Frankel, Jeffrey
Staskin, David
Varano, Susann
Kennelly, Michael
Newman, Diane K.
Rosenberg, Matt T.
Jankowich, Rachael A.
Shortino, Denise
Mudd, Paul N. Jr
Girman, Cynthia J.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
https://doi.org/10.1007/s12325-021-01972-8
Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
https://doi.org/10.1007/s40266-020-00829-z
Funding for this research was provided by:
Urovant Sciences
Article History
Received: 23 August 2021
Accepted: 20 October 2021
First Online: 18 December 2021